These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 6340081)
1. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. DeWys WD; Begg CB; Brodovsky H; Creech R; Khandekar J Prostate; 1983; 4(1):1-11. PubMed ID: 6340081 [TBL] [Abstract][Full Text] [Related]
2. Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer. DeWys WD Cancer Chemother Rep; 1975; 59(1):215-7. PubMed ID: 1093668 [No Abstract] [Full Text] [Related]
3. Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma. Collier D; Soloway MS Urology; 1976 Nov; 8(5):459-64. PubMed ID: 982733 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. Merrin C; Etra W; Wajsman Z; Baumgartner G; Murphy G J Urol; 1976 Jan; 115(1):86-8. PubMed ID: 1107604 [TBL] [Abstract][Full Text] [Related]
5. Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer--progress report. DeWys WD; Bauer M; Colsky J; Cooper RA; Creech R; Carbone PP Cancer Treat Rep; 1977; 61(2):325-8. PubMed ID: 326401 [No Abstract] [Full Text] [Related]
6. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313 [TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease. Citrin DL; Elson P; DeWys WD Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984 [TBL] [Abstract][Full Text] [Related]
8. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report. Eagan RT; Utz DC; Myers RP; Furlow WL Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666 [TBL] [Abstract][Full Text] [Related]
9. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Citrin DL; Hogan TF Cancer; 1982 Jul; 50(2):201-6. PubMed ID: 7200827 [TBL] [Abstract][Full Text] [Related]
10. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Eagan RT; Hahn RG; Myers RP Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515 [No Abstract] [Full Text] [Related]
11. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. Levi JA; Fox RM; Tattersall MH; Woods RL; Thomson D; Gill G J Clin Oncol; 1986 Sep; 4(9):1348-55. PubMed ID: 3528404 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Oster MW; Gray R; Panasci L; Perry MC Cancer; 1986 Jan; 57(1):29-33. PubMed ID: 2934124 [TBL] [Abstract][Full Text] [Related]
13. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. Murphy GP; Priore RL; Scardino PT Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371 [TBL] [Abstract][Full Text] [Related]
14. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219 [TBL] [Abstract][Full Text] [Related]
15. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer. Haller DG; Woolley PV; Macdonald JS; Smith LF; Schein PS Cancer Treat Rep; 1978 Apr; 62(4):563-5. PubMed ID: 350394 [TBL] [Abstract][Full Text] [Related]
17. 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Smith FP; Hoth DF; Levin B; Karlin DA; MacDonald JS; Woolley PV; Schein PS Cancer; 1980 Nov; 46(9):2014-8. PubMed ID: 7427908 [TBL] [Abstract][Full Text] [Related]
18. The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice. Drago JR; Maurer RE; Gershwin ME; Eckels D; Palmer JM Cancer; 1979 Aug; 44(2):424-30. PubMed ID: 476560 [TBL] [Abstract][Full Text] [Related]
19. A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. Smith BJ; Ashford RF; Bakowski M; Hellman K; Newton K; Phillips R; Lambert J; Jones R; Peters N; Evans M Am J Clin Oncol; 1983 Aug; 6(4):481-4. PubMed ID: 6346856 [TBL] [Abstract][Full Text] [Related]